ADC class landscape, 2026 mid-year reference

Reference layout of the antibody-drug conjugate class in oncology as of mid-2026. Includes approved assets by target and indication, late-stage pipeline by mechanism, and the live differentiation axes the field is settling on. Useful as a quick orientation for cross-functional teams entering the ADC conversation, with deeper analysis available in companion gated Briefs across the breast cancer, lung cancer and gastric cancer indications.